THERAPY DOSSIER · th-3113392492b8

Recombinant human connective tissue growth factor (CTGF/CCN2), with a CTGF function-blocking antibody, delivered in the context of sFRP2-overexpressing or GFP control mesenchymal stem cells

Biologic · Biologic (recombinant CTGF + CTGF function-blocking antibody); the anti-CTGF antibody class (FG-3019/pamrevlumab) reached clinical trials

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Biologic (recombinant CTGF + CTGF function-blocking antibody); the anti-CTGF antibody class (FG-3019/pamrevlumab) reached clinical trials
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01217632 ↗PHASE2terminated

FG-3019 (anti-CTGF antibody) in Liver Fibrosis Due to Chronic Hepatitis B

Liver Fibrosis

Enrolment: 114 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23212098 ↗2012Mixed findings

A physiological role for connective tissue growth factor in early wound healing.

MouseWoundC57Bl/6 wild-type, plus CTGF haploinsufficient mice and wild-type littermatesn = Sponge time course GFP-MSCs n=18, sFRP2-MSCs n=18, saline n…Local injection into subcutaneously implanted polyvinyl alcohol sponges, and soak loading of sponges before implantationRecombinant CTGF 1 microgram per sponge in 10 microlitres;…Antibody or IgG admixed with MSCs at sponge implantation with injections from 2…

Model: Polyvinyl alcohol sponge (6 mm) implanted in ventral subcutaneous pockets as a granulation tissue model; 6 mm full-thickness excisional dorsal wounds, including a stented cohort with a 10 mm silicone splint; human partial-thickness burn wound margins studied in parallel

Blocking CTGF during the first 7 days reduced the quantity, organisation and vascularity of mesenchymal stem cell derived granulation tissue (31.3 plus or minus 3.8 per cent versus 40 plus or minus 2.3 per cent, p<0.05), supporting a pro-reparative role for early CTGF. Prolonged recombinant CTGF ov…

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…